Accessibility Menu
Cingulate logo

Cingulate(NASDAQ) CING

Market Cap$66.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year-13%
1 Month-9%
$4.95
+1.02%
+0.05Today
After hours$4.94-$0.01 (-0.20%)
Cingulate last closing stock price
MetricPriceDate
Last closeUSD 4.902026-08-04
Cingulate stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.17%USD 4.532026-07-28
1 month-8.92%USD 5.382026-07-02
3 month-8.07%USD 5.332026-05-06
Year to date+12.9%USD 4.342025-12-31
1 year-12.66%USD 5.612025-08-04
3 year-96.24%USD 130.202023-08-04
Since inception-99.54%USD 1,068.002021-12-08

Cingulate Financials at a Glance

Market Cap

$66.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$27.71M

EPS (TTM)

-$4.26

P/E Ratio

-1.15

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$4.95

Volume

115,798.571

Open

$4.96

Previous Close

$4.90

Daily Range

$4.91 - $5.10

52-Week Range

$3.16 - $11.89

Estimated Earnings Date

Aug 18, 2026

CING News

Foolcom-Featured.png

Cingulate Posts Wider Loss in Q2

Motley Fool Markets TeamAug 19, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cingulate

Cingulate develops new medicines for attention and anxiety disorders. Its main products aim to help people manage daily focus and stress. The company uses special tablet technology for controlled, all-day effects.

What’s in the Cingulate Medicine Cabinet?

  • CTx-1301 (dexmethylphenidate): Lead product for attention-deficit/hyperactivity disorder (ADHD); targets children, teens, and adults. 0% of revenue (pre-commercial).
  • CTx-1302 (dextroamphetamine): Second ADHD candidate; clinical plans depend on new funding. 0% of revenue (pre-commercial).
  • CTx-2103 (buspirone): Early-stage product for anxiety disorders; not yet in human trials. 0% of revenue (pre-commercial).
  • Precision Timed Release tablets: Tablets designed to release medicine at set times for steady symptom control.
  • Commercialization services: U.S. partnership with Indegene for future marketing, sales, and safety monitoring.

Growth Spurts and Strategic Moves

  • Submitted CTx-1301 for U.S. regulatory approval in July 2025.
  • Signed commercialization agreement with Indegene in 2025 for U.S. launch support.
  • Secured up to $25 million equity financing from Lincoln Park Capital in July 2025.
  • Renewed Kansas City headquarters lease for five years in June 2025.
  • Entered manufacturing agreements with Societal in 2025 and made milestone payments to BDD Pharma under an existing agreement.

Why Cingulate Is a Bit Different

Cingulate focuses on once-daily tablets that release medicine in timed phases, aiming for steady symptom relief. Its business model relies on partnerships for commercialization and manufacturing. The company operates only in the U.S. and has not yet launched any products.

Five Things You Need to Know

  • No revenue reported for Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Operating loss was $5 million in Q2 2025, up 45% from Q2 2024.
  • Cash and equivalents were $8.9 million as of June 30, 2025.
  • R&D expenses rose 43.6% year-over-year to $2.7 million in Q2 2025.
  • Company has 13 employees and a market cap of $18.03 million in Q2 2025.

Bottom Line

Cingulate remains a pre-revenue biotech focused on ADHD and anxiety treatments. Its future depends on regulatory approval and new funding.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

14

CEO

Shane J. Schaffer, PharmD

Website

www.cingulate.com

Headquarters

Kansas City, KS 66205, US

CING Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-365.16%

Return on Capital

-176.51%

Return on Assets

-89.80%

Earnings Yield

-86.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$66.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

13.47M

Volume

115.80K

Avg. Volume

479.09K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$24.16M

EBITDA

-$23.66M

Operating Cash Flow

-$19.55M

Capital Expenditure

-$223.31K

Free Cash Flow

-$19.77M

Cash & ST Invst.

$25.89M

Total Debt

$7.43M

Cingulate Performance Analysis

Cingulate annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Cingulate sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Cingulate annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -375.11-14.6%
20232023-12-31USD -311.99-16.8%
20242024-12-31USD -10.86-96.5%
20252025-12-31USD -4.44-59.1%
Cingulate sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-4.8%
Q32025-09-30-23.9%
Q42025-12-3135.6%
Q12026-03-31-96.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$66.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.71M

N/A

Employees

14

N/A

Net Income

-$9.31M

-141.7%

EBITDA

-$7.80M

-120.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$25.89M

+172.0%

Total Debt

$7.43M

+46.2%

Accounts Receivable

$53.94K

+29.7%

Inventory

$0.00

N/A

Long Term Debt

$1.04M

+12.1%

Short Term Debt

$6.39M

+53.8%

Return on Assets

-89.80%

N/A

Return on Invested Capital

-1.21%

N/A

Free Cash Flow

-$6.97M

-51.3%

Operating Cash Flow

-$6.91M

-50.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LIXTLixte Biotechnology Holdings, Inc.
$7.21-6.00%
ALLRAllarity Therapeutics, Inc.
$1.33+1.53%
SYBXSynlogic, Inc.
$1.18+0.00%
ENTOEntero Therapeutics, Inc.
$2.85-5.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$109.67-0.12%
NVDANvidia
$220.94+0.04%
ONDSOndas
$8.90+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.83-0.03%

Questions About CING

What is the current price of Cingulate?

Cingulate is trading at $4.96 per share.

What is the 52-week range for Cingulate?

Over the past 52 weeks, Cingulate has traded between $3.16 and $11.89.

How much debt does Cingulate have?

As of the most recent reporting period, Cingulate reported total debt of $7.43M.

How much cash does Cingulate have on hand?

Cingulate reported $25.89M in cash and cash equivalents in its most recent financial results.

What is Cingulate’s dividend yield?

Cingulate does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services